Don’t Miss This Vital Piece of Information About Your Patient’s Heart Disease Risk
In the United States, someone has a heart attack every 34 seconds and someone dies of heart disease every 60 seconds.1 Half of all cardiac events occur in people with normal to low cholesterol levels and even while taking statin therapy, there is a 70% risk of having a cardiac event.2 Don’t lose focus of a patient’s actual heart disease risk while chasing after total cholesterol and LDL numbers. What you really need to know is oxLDL.
OxLDL Predicts the Progression of Heart Disease and Plaque Formation in the Arteries
Research from Journal of the American Medical Association, Journal of Internal Medicine, and Circulation confirm that we can finally predict the risk of heart disease, even if symptoms do not present themselves, and in patients with no previous history of heart disease. While low-density lipoprotein (LDL) is often called, “the bad cholesterol,” oxLDL is a more reliable indicator of plaque formation in arteries.8
Oxidized low-density lipoprotein (oxLDL) is LDL that has been damaged by free radicals.3 It increases inflammation and increases lipid deposits in the arterial wall, making it a key player in the progression of atherogenesis.4 oxLDL has been elevated in all stages of atherosclerosis, including early atherogenesis and hypertension, coronary and peripheral artery diseases, acute coronary syndromes, and stroke.4-6
If you are managing patients with heart disease, oxLDL is a piece of information you- and your patients- cannot live without.
Conditions Associated with High Oxidized LDL
- Acute coronary syndrome
- Acute myocardial infarction (AMI)
- Coronary artery disease (CAD)
- Early atherogenesis
- Inflammatory bowel disease
- Metabolic syndrome
- Multiple sclerosis (MS)
- Peripheral artery disease
- Polycystic ovary syndrome (PCOS)
- Rheumatoid arthritis
- Stenosis of coronary arteries
- Type 2 diabetes
Oxidized LDL Testing Options
Precision Point Diagnostics offers oxLDL standalone or with lipids. Oxidized LDL with Lipids Profile gives oxLDL with total cholesterol, LDL, high density lipoprotein (HDL), very low-density lipoprotein (VLDL), and triglycerides. A high oxLDL:HDL Ratio did a better job than traditional lipid markers when discriminating between patients with coronary artery disease and healthy subjects (Table 1).7 To promote good clinical outcomes, we provide comprehensive interpretive materials with specific treatment ideas commonly used by your fellow practitioners. Together with other markers of heart health, oxLDL gives you a critical piece of information necessary to address the underlying pathology of your patient’s heart disease.
1. Heart Disease Facts. 2014; http://www.theheartfoundation.org/heart-disease-facts/heart-disease-statistics/. Accessed July 16, 2015.
2. Dallmeier D, Koenig W. Strategies for vascular disease prevention: the role of lipids and related markers including apolipoproteins, low-density lipoproteins (LDL)-particle size, high sensitivity C-reactive protein (hs-CRP), lipoprotein-associated phospholipase A2 (Lp-PLA(2)) and lipoprotein(a) (Lp(a)). Best Pract Res Clin Endocrinol Metab. 2014;28(3):281-294.
3. Thomas SR, Leichtweis SB, Pettersson K, et al. Dietary cosupplementation with vitamin E and coenzyme Q(10) inhibits atherosclerosis in apolipoprotein E gene knockout mice. Arteriosclerosis, thrombosis, and vascular biology. 2001;21(4):585-593.
4. Trpkovic A, Resanovic I, Stanimirovic J, et al. Oxidized low-density lipoprotein as a biomarker of cardiovascular diseases. Critical reviews in clinical laboratory sciences. 2015;52(2):70-85.
5. Pang H, Han B, Li ZY, Fu Q. Identification of molecular markers in patients with hypertensive heart disease accompanied with coronary artery disease. Genetics and molecular research : GMR. 2015;14(1):93-100.
6. Gruzdeva O, Uchasova E, Dyleva Y, et al. Multivessel coronary artery disease, free fatty acids, oxidized LDL and its antibody in myocardial infarction. Lipids in health and disease. 2014;13:111.
7. Johnston N, Jernberg T, Lagerqvist B, Siegbahn A, Wallentin L. Improved identification of patients with coronary artery disease by the use of new lipid and lipoprotein biomarkers. The American journal of cardiology. 2006;97(5):640-645.